ReviewFrontiers in physiology2026
Exosomes in osteoporosis: regulatory mechanisms and clinical applications.
Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exosomes in Metabolic Bone Diseases: Regulators, Biomarkers and Targeted Delivery Systems.Biomedicines · 2026Review
- From Molecular Pathways to Artificial Intelligence: Advancing the Understanding and Management of Osteosarcopenia.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a systemic metabolic bone disorder characterized by progressive bone mass reduction and microarchitectural deterioration, leading to fragility fractures. It poses a serious threat to the health of middle-aged and elderly populations and imposes a heavy healthcare burden. Exosomes mediate intercellular communication by transporting bioactive molecules such as proteins, miRNAs, and circRNAs, exerting bidirectional regulation on bone homeostasis. Exosomes derived from mesenchymal stem cells, young plasma, and plants often improve osteoporosis by promoting osteoblastic differentiation and suppressing osteoclastic activity. Conversely, exosomes originating from osteoclasts, M1 macrophages, and tumor cells tend to accelerate bone resorption. Exosomes not only provide highly specific non-invasive biomarkers for osteoporosis but also emerge as novel therapeutic carriers due to their inherent biocompatibility, targeted delivery properties, and potential for engineered modification. This systematic review examines the biological properties of exosomes, the molecular mechanisms by which exosomes from different sources regulate bone metabolism, and their application progress in the diagnosis and treatment of osteoporosis. It also explores challenges in their clinical translation, providing a comprehensive reference for further research and clinical application in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.